Adding TACE to Lenvatinib Improves Survival in Liver Cancer

Transarterial chemoembolization (TACE) added onto lenvatinib is a new first-line option for patients with advanced liver cancer, say LAUNCH trialists.

Related Keywords

China , Guangzhou , Guangdong , Ming Kuang , Anhui , , Sun Yat Sen University , First Affiliated Hospital , Hepatocellular Carcinoma , Liver Cancer , Dcc , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Gastrointestinal Malignancy , I Malignancy , Hepatitis B , Bv Hepatitisb Virus , Hospitals , Inpatient Care , Liver ,